Cybin Inc. CYBN a company developing novel psychedelic compounds for therapeutic use, has received a Schedule I manufacturing license from the U.S. Drug Enforcement Agency (DEA).
The DEA license is a federal requirement for any investigators intending to study, produce or analyze Schedule I substances. Before obtaining the license, Cybin conducted much of its R&D work through globally-licensed research organizations in the U.S., Canada, the U.K. and through certain in-house capabilities.
“With the DEA license, the company will be able to vastly expand its internal R&D capabilities to support innovative drug discovery and delivery involving Schedule I compounds,” the company announced in a press release.
“We are pleased with the progression of our clinical and regulatory efforts since the company's formation,” said CEO Doug Drysdale. "This new license further positions the company as a truly integrated biopharmaceutical company that can continue to work towards progressing psychedelics to therapeutics.”
On Monday, November 8, Cybin will hold a research and development event to review its breakthrough findings for Q4 2021, in a live setting at Wonderland, the Miami psychedelics conference.
Results unveiled at the event could spark a shift in the company’s price action.
Image by felixioncool from Pixabay.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.